Who are CYCLOSPORINE's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sandimmune, Once Daily Tacrolimus, Cyclosporin A (CsA), Topical tacrolimus, tacrolimus, low dose, Cyclosporin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl160.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CYCLOSPORINE — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CYCLOSPORINE (CYCLOSPORINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin Inhibitor Immunosuppressant [EPC].

marketed Calcineurin Inhibitor Immunosuppressant [EPC] calcineurin Recombinant protein Live · refreshed every 30 min

Target snapshot

CYCLOSPORINE (CYCLOSPORINE). Cyclosporine, a calcineurin inhibitor, selectively modulates the immune system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CYCLOSPORINE TARGET	CYCLOSPORINE		marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	calcineurin	1983-01-01
Sandimmune	cyclosporine	Novartis AG (originally Sandoz)	marketed	Calcineurin inhibitor (immunosuppressant)	Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2	1983-11-14
Once Daily Tacrolimus	Once Daily Tacrolimus	University of Saskatchewan	marketed	Calcineurin inhibitor	Calcineurin (via FKBP12 binding)
Cyclosporin A (CsA)	Cyclosporin A (CsA)	Peking Union Medical College Hospital	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)
Topical tacrolimus	Topical tacrolimus	The Catholic University of Korea	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)
tacrolimus, low dose	tacrolimus, low dose	Hoffmann-La Roche	marketed	Calcineurin inhibitor	Calcineurin (protein phosphatase 2B)
Cyclosporin	Cyclosporin	Karolinska University Hospital	marketed		Calcineurin subunit B type 1, Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-11-03 — Sandimmune · 8298568 · Formulation · US
2029-06-02 — Sandimmune · 9132071 · Formulation · US
2030-12-13 — Sandimmune · 8614178 · Formulation · US
2031-02-25 — Sandimmune · 8292129 · Formulation · US
2032-04-16 — Sandimmune · 8561859 · Formulation · US
2033-08-23 — Sandimmune · 8980839 · Formulation · US
2033-08-23 — Sandimmune · 10441630 · Formulation · US
2033-08-23 — Sandimmune · 9937225 · Formulation · US
2034-02-07 — Sandimmune · 9676525 · Formulation · US
2034-05-11 — Sandimmune · 9669974 · Formulation · US
2036-09-29 — Sandimmune · 12496326 · Method of Use · US
2037-02-28 — Sandimmune · 11951153 · Method of Use · US
2037-02-28 — Sandimmune · 10918694 · Formulation · US
2037-09-22 — Sandimmune · 10813976 · Formulation · US
2038-11-20 — Sandimmune · 11154513 · Formulation · US
2039-10-11 — Sandimmune · 11413323 · Method of Use · US
2042-04-01 — Sandimmune · 12059449 · Formulation · US

Sponsor landscape (Calcineurin Inhibitor Immunosuppressant [EPC] class)

· 1 drug in this class
Bausch Health · 1 drug in this class
Novartis · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CYCLOSPORINE — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl160. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing